Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKD

Introduction - Soluble urokinase plasminogen activation receptor (suPAR) is an immune-derived pathogenic factor for kidney and atherosclerotic disease. Whether the association between suPAR and cardiovascular (CV) outcomes is dependent on the severity of underlying kidney disease is unclear. - Metho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sommerer, Claudia (VerfasserIn) , Müller-Krebs, Sandra (VerfasserIn) , Nadal, Jennifer (VerfasserIn) , Schultheiß, Ulla Teresa (VerfasserIn) , Friedrich, Nele (VerfasserIn) , Nauck, Matthias (VerfasserIn) , Schmid, Matthias (VerfasserIn) , Nußhag, Christian (VerfasserIn) , Reiser, Jochen (VerfasserIn) , Eckardt, Kai-Uwe (VerfasserIn) , Zeier, Martin (VerfasserIn) , Hayek, Salim (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 9 September 2023
In: Kidney international. Reports
Year: 2023, Jahrgang: 8, Heft: 11, Pages: 2265-2275
ISSN:2468-0249
DOI:10.1016/j.ekir.2023.08.038
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ekir.2023.08.038
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2468024923014754
Volltext
Verfasserangaben:Claudia Sommerer, Sandra Müller-Krebs, Jennifer Nadal, Ulla T. Schultheiss, Nele Friedrich, Matthias Nauck, Matthias Schmid, Christian Nußhag, Jochen Reiser, Kai-Uwe Eckardt, Martin Zeier and Salim S. Hayek on behalf of the German Chronic Kidney Disease Investigators

MARC

LEADER 00000caa a2200000 c 4500
001 1883749301
003 DE-627
005 20250116011404.0
007 cr uuu---uuuuu
008 240319s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.ekir.2023.08.038  |2 doi 
035 |a (DE-627)1883749301 
035 |a (DE-599)KXP1883749301 
035 |a (OCoLC)1443657332 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Sommerer, Claudia  |d 1971-  |e VerfasserIn  |0 (DE-588)121857654  |0 (DE-627)705680002  |0 (DE-576)292921829  |4 aut 
245 1 0 |a Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKD  |c Claudia Sommerer, Sandra Müller-Krebs, Jennifer Nadal, Ulla T. Schultheiss, Nele Friedrich, Matthias Nauck, Matthias Schmid, Christian Nußhag, Jochen Reiser, Kai-Uwe Eckardt, Martin Zeier and Salim S. Hayek on behalf of the German Chronic Kidney Disease Investigators 
264 1 |c 9 September 2023 
300 |b Diagramme 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 19.3.2024 
520 |a Introduction - Soluble urokinase plasminogen activation receptor (suPAR) is an immune-derived pathogenic factor for kidney and atherosclerotic disease. Whether the association between suPAR and cardiovascular (CV) outcomes is dependent on the severity of underlying kidney disease is unclear. - Methods - We measured serum suPAR levels in 4994 participants (mean age 60 years; 60% men; 36% with diabetes mellitus; mean estimated glomerular filtration rate (eGFR) 49 ml/min per 1.73 m2, SD 18) of the German Chronic Kidney Disease (GCKD) cohort and examined its association with all-cause death, CV death, and major CV events (MACE) across the range of eGFR and urine albumin-to-creatinine ratio (UACR). - Results - The median suPAR level was 1771 pg/ml (interquartile range [IQR] 1447-2254 pg/ml). SuPAR levels were positively and independently correlated with age, eGFR, UACR, and parathyroid hormone levels. There were 573 deaths, including 190 CV deaths and 683 MACE events at a follow-up time of 6.5 years. In multivariable analyses, suPAR levels (log2) were associated with all-cause death (hazard ratio [HR] 1.36, 95% confidence interval [CI] 1.21-1.53), CV death (HR 1.27, 95% CI 1.03-1.57), and MACE (HR 1.13, 95% CI 1.00-1.28), and were not found to differ according to diabetes mellitus status, baseline eGFR, UACR, or parathyroid hormone levels. In mediation analysis, suPAR’s direct effect on all-cause death, CV death, and MACE accounted for 77%, 67%, and 60% of the total effect, respectively; whereas the effect mediated through eGFR accounted for 23%, 34%, and 40%, respectively. - Conclusion - In a large cohort of individuals with chronic kidney disease (CKD), suPAR levels were associated with mortality and CV outcomes independently of indices of kidney function, consistent with its independent role in the pathogenesis of atherosclerosis. 
650 4 |a biomarkers 
650 4 |a cardiovascular outcomes 
650 4 |a cohort 
650 4 |a eGFR 
650 4 |a suPAR 
650 4 |a uACR 
700 1 |a Müller-Krebs, Sandra  |e VerfasserIn  |0 (DE-588)1163760765  |0 (DE-627)1028122519  |0 (DE-576)508203996  |4 aut 
700 1 |a Nadal, Jennifer  |e VerfasserIn  |4 aut 
700 1 |a Schultheiß, Ulla Teresa  |d 1979-  |e VerfasserIn  |0 (DE-588)132363488  |0 (DE-627)690532822  |0 (DE-576)299099148  |4 aut 
700 1 |a Friedrich, Nele  |d 1980-  |e VerfasserIn  |0 (DE-588)135701899  |0 (DE-627)569735432  |0 (DE-576)300595867  |4 aut 
700 1 |a Nauck, Matthias  |e VerfasserIn  |4 aut 
700 1 |8 1\p  |a Schmid, Matthias  |e VerfasserIn  |0 (DE-588)1068404426  |0 (DE-627)820226939  |0 (DE-576)42775707X  |4 aut 
700 1 |a Nußhag, Christian  |d 1985-  |e VerfasserIn  |0 (DE-588)1054789827  |0 (DE-627)792121376  |0 (DE-576)410521280  |4 aut 
700 1 |a Reiser, Jochen  |d 1971-  |e VerfasserIn  |0 (DE-588)121353818  |0 (DE-627)705405796  |0 (DE-576)181508850  |4 aut 
700 1 |a Eckardt, Kai-Uwe  |d 1960-  |e VerfasserIn  |0 (DE-588)110507835  |0 (DE-627)521900182  |0 (DE-576)289675502  |4 aut 
700 1 |a Zeier, Martin  |e VerfasserIn  |0 (DE-588)1026480302  |0 (DE-627)726772356  |0 (DE-576)371826438  |4 aut 
700 1 |a Hayek, Salim  |d 1958-  |e VerfasserIn  |0 (DE-588)1214408273  |0 (DE-627)1725474409  |4 aut 
773 0 8 |i Enthalten in  |t Kidney international. Reports  |d Amsterdam : Elsevier, 2016  |g 8(2023), 11 vom: Nov., Seite 2265-2275  |h Online-Ressource  |w (DE-627)881695580  |w (DE-600)2887223-X  |w (DE-576)485146266  |x 2468-0249  |7 nnas  |a Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKD 
773 1 8 |g volume:8  |g year:2023  |g number:11  |g month:11  |g pages:2265-2275  |g extent:11  |a Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKD 
856 4 0 |u https://doi.org/10.1016/j.ekir.2023.08.038  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S2468024923014754  |x Verlag  |z kostenfrei  |3 Volltext 
883 |8 1\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
951 |a AR 
992 |a 20240319 
993 |a Article 
994 |a 2023 
998 |g 1026480302  |a Zeier, Martin  |m 1026480302:Zeier, Martin  |d 50000  |d 910000  |d 910100  |e 50000PZ1026480302  |e 910000PZ1026480302  |e 910100PZ1026480302  |k 0/50000/  |k 0/910000/  |k 1/910000/910100/  |p 11 
998 |g 1054789827  |a Nußhag, Christian  |m 1054789827:Nußhag, Christian  |d 50000  |e 50000PN1054789827  |k 0/50000/  |p 8 
998 |g 121857654  |a Sommerer, Claudia  |m 121857654:Sommerer, Claudia  |d 50000  |e 50000PS121857654  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1883749301  |e 4501547847 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"disp":"Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKDKidney international. Reports","recId":"881695580","part":{"extent":"11","text":"8(2023), 11 vom: Nov., Seite 2265-2275","volume":"8","pages":"2265-2275","issue":"11","year":"2023"},"id":{"issn":["2468-0249"],"zdb":["2887223-X"],"eki":["881695580"]},"origin":[{"publisherPlace":"Amsterdam","dateIssuedDisp":"[2016]-","publisher":"Elsevier"}],"language":["eng"],"pubHistory":["Volume 1, issue 1 (May 2016)-"],"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 23.06.20"],"titleAlt":[{"title":"KI reports"},{"title":"Kidney international reports"}],"title":[{"title_sort":"Kidney international","title":"Kidney international","partname":"Reports"}]}],"note":["Gesehen am 19.3.2024"],"name":{"displayForm":["Claudia Sommerer, Sandra Müller-Krebs, Jennifer Nadal, Ulla T. Schultheiss, Nele Friedrich, Matthias Nauck, Matthias Schmid, Christian Nußhag, Jochen Reiser, Kai-Uwe Eckardt, Martin Zeier and Salim S. Hayek on behalf of the German Chronic Kidney Disease Investigators"]},"recId":"1883749301","id":{"eki":["1883749301"],"doi":["10.1016/j.ekir.2023.08.038"]},"origin":[{"dateIssuedDisp":"9 September 2023","dateIssuedKey":"2023"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"11 S.","noteIll":"Diagramme"}],"person":[{"display":"Sommerer, Claudia","family":"Sommerer","given":"Claudia","role":"aut"},{"display":"Müller-Krebs, Sandra","family":"Müller-Krebs","role":"aut","given":"Sandra"},{"display":"Nadal, Jennifer","role":"aut","given":"Jennifer","family":"Nadal"},{"display":"Schultheiß, Ulla Teresa","family":"Schultheiß","role":"aut","given":"Ulla Teresa"},{"family":"Friedrich","given":"Nele","role":"aut","display":"Friedrich, Nele"},{"role":"aut","given":"Matthias","family":"Nauck","display":"Nauck, Matthias"},{"display":"Schmid, Matthias","family":"Schmid","role":"aut","given":"Matthias"},{"given":"Christian","role":"aut","family":"Nußhag","display":"Nußhag, Christian"},{"family":"Reiser","role":"aut","given":"Jochen","display":"Reiser, Jochen"},{"display":"Eckardt, Kai-Uwe","role":"aut","given":"Kai-Uwe","family":"Eckardt"},{"given":"Martin","role":"aut","family":"Zeier","display":"Zeier, Martin"},{"given":"Salim","role":"aut","family":"Hayek","display":"Hayek, Salim"}],"title":[{"title":"Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKD","title_sort":"Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKD"}]} 
SRT |a SOMMERERCLPROSPECTIV9202